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OBJECTIVES We sought to evaluate the common utilization of beta-blockers and angiotensin-converting
enzyme (ACE) inhibitors or receptor blockers (RBs) in congestive heart failure (CHF).
BACKGROUND We assessed the association between prescriptions of beta-blockers and ACE inhibitors or
RBs within three months after hospitalization and mortality for newly diagnosed CHF in
Alberta, Canada seniors (age 65 years and older).
METHODS Administrative hospital discharge abstracts and drug data during October 1, 1994, to
December 31, 1999, were analyzed.
RESULTS There were 11,854 hospitalizations for newly diagnosed CHF. The use of beta-blockers
within three months after hospitalization increased from 7.3% in 1994–1995 to 20.9% in
1999–2000. The use of ACE inhibitor or RBs within three months after hospitalization
increased from 31.0% in 1994–1995 to 44.3% in 1999–2000. Adjusted one-year mortality
was lower in seniors with prescriptions for beta-blockers (18.2%; 95% confidence interval [CI]
14.2 to 22.2), ACE inhibitors/RBs (22.3%; 95% CI 20.9 to 23.7), or both (16.6%; 95% CI
13.3 to 20.0), compared with those with no prescriptions (29.9%; 95% CI 28.8 to 31.0).
Absolute adjusted risk reduction comparing no prescription with prescription of both
beta-blockers or ACE inhibitors/RBs was 13.3% for a relative adjusted risk reduction of 44%.
CONCLUSIONS This study of incident CHF hospitalizations among seniors demonstrates an association
between decreased mortality and the use of beta-blockers, ACE inhibitors/RBs, or combi-
nation of both. The effectiveness of beta-blockers and ACE inhibitors/RBs for CHF should
be more broadly tested in clinical trials that recruit older patients and those with diastolic
dysfunction. (J Am Coll Cardiol 2003;42:1438–45) © 2003 by the American College of
Cardiology Foundation
Congestive heart failure (CHF) is the most common diag-
nosis for hospital admission in the U.S. (1) and other
industrialized countries (2–6). Despite the increased inci-
dence, mortality has declined, suggesting that recent therapy
may have improved outcomes (7,8). In randomized clinical
trials, beta-blockers and angiotensin-converting enzyme
(ACE) inhibitors or receptor blockers (RBs) reduced mor-
tality (9). Despite proven efficacy in clinical trials, physician
prescription practices vary depending on system supports
(10–15), which, if not present, may result in suboptimal
utilization of these pharmaceuticals (16,17). Physicians may
also be reluctant to extrapolate results from clinical trials
that excluded patients older than 75 years and only enrolled
patients with low ejection fractions (9). These older patients
constituted up to 50% of hospitalizations for newly diag-
nosed CHF, and a low ejection fraction was not present in
up to 50% of patients with the hospital admission diagnosis
of CHF (14,18,19).
Using administrative data, we analyzed the prescription
pattern in seniors taking beta-blockers and ACE inhibitors/
RBs within three months after hospitalization for newly
diagnosed CHF during October 1, 1994, to December 31,
1999. To better understand prescription practices, we as-
sessed patient, geographic, and physician factors that may
have influenced the utilization of therapy. Finally, after
adjusting for comorbidity and CHF severity, we assessed the
association between the utilization of therapy and one-year
mortality. We hypothesized that the efficacy demonstrated
in clinical trials would extrapolate into efficacious therapy
for the population of one Canadian province.
METHODS
The following administrative data sources were used for this
study: 1) the Canadian Institute for Health Information’s
Inpatient Discharge Abstract Database for the province of
Alberta for fiscal years 1992–1993 to 1999–2000; and 2) the
Alberta Health Insurance Plan Registry File for fiscal years
1994–1995 to 2000–2001, the Alberta Physician Claims
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Assessment System Database for 1992–1993 to 1999–2000,
and the Alberta Blue Cross Insurance plan for fiscal years
1994–1995 to 1999–2000.
Study population. The in-hospital discharge abstract data
for the province of Alberta, Canada, during the fiscal years
1994–1995 to 1999–2000 were used to define the study
population. The in-hospital discharge abstract data capture
sociodemographic and clinical information of inpatients
admitted to all hospitals in Alberta. All hospitals in Alberta
are administered by an autonomous regional board in each
of the 17 health regions. Nearly all of three million residents
of Alberta are enrolled in the public health care insurance
plan. Firstly, we identified heart failure patients by searching
the validated and widely used International Classification of
Disease, Ninth Revision, Clinical Modification (ICD-9-
CM) diagnostic codes (428.x, 398.91, 402.x1, 404.1– 404.9,
514.x, 518.4, 425.9) in the most responsible diagnosis field
(20,21). Secondly, we excluded patients who met the fol-
lowing criteria:
1) not an Alberta resident;
2) age 20 years or 105 years; and
3) admission to an Alberta non–acute care facility. Thirdly,
to identify “incidence” cases;
4) we linked patients thus defined with the inpatient
discharge abstract from 1992–1993 to 1999–2000 and
excluded patients hospitalized for heart failure (as the
most responsible diagnosis) during the two fiscal years
before the index encounter;
5) we excluded admissions if the same patient had an later
hospital discharge within the five study years; and
6) we excluded patients with an outpatient internal medi-
cine specialist/subspecialist consultation claim (22) for
heart failure (defined as for hospitalizations) during the
two years before the index encounter.
Study Variables
Sociodemographic variables and transfers. PATIENT
CHARACTERISTICS. The patients’ sociodemographic and
geographic characteristics were defined during the index
admission, including: 1) age (65–74, 75–84, and 85
years); 2) gender; 3) year of heart failure hospital discharge;
4) region of residence (the 17 health regions in Alberta were
grouped into two metropolitan regions [Calgary and Edm-
onton] and one nonmetropolitan region); and 5) exported
patient (patient admission to a hospital located in a health
region not within the health region of residence). We also
defined residents of a nursing home, long-term care facility,
or senior’s lodge before the hospital admission.
Transfers to another acute care hospital where the receiv-
ing hospital also identified heart failure as the primary
reason for admission were identified through linking the
study population and the inpatient discharge abstract during
1994–1995 to 1999–2000. Cases with a one-day difference
between the discharge date of the index admission and the
second admission date were assigned as transfers. Dis-
charges and admissions for heart failure to the same hospital
within 24 h were counted as separate admissions.
Case-mix and severity of disease. Case-mix and severity
of disease were defined using diagnoses coded in the index
and transferred admission. For case-mix, we defined the 17
comorbidities that constitute the Charlson index (23,24),
using Deyo’s coding algorithm by searching the 15 supple-
mental diagnosis fields in the hospital abstract. The Charl-
son comorbidities were aggregated into none, one, two, or
more of the individual conditions. To define severity of
comorbidities, we employed Polanczyk’s weight scale (25).
We defined: 1) anemia (ICD-9-CM 280.xx to 285.xx); 2)
hyponatremia and other electrolyte disturbance (ICD-
9-CM 276.x); 3) coronary artery disease (ICD-9-CM
411.xx, 413.xx, 414.xx); 4) hypertension (ICD-9-CM
401.xx to 405.xx); 5) valvular heart disease (ICD-9-CM
394.xx to 398.xx, 424.xx); 6) ventricular arrhythmia (ICD-
9-CM 427.4x, 427.5x, 427.6x); and 7) hypotension and
shock (ICD-9-CM 458.xx, 758.5x). Then we assigned a
severity score (25) for each patient by using the following
weighting method: 1 point for age 40 years; increasing 1
point per decade of age 40 years; 2 points for each of the
comorbidities of transferred admission, cerebral vascular
disease, chronic obstructive lung disease, hyponatremia,
other electrolyte disturbance, and metastatic disease; 4
points for the comorbidity of moderate to severe renal
disease; 6 points for each of the comorbidities of ventricular
arrhythmia, mild liver disease, and malignancy; and 13
points for each of the comorbidities of hypotension, shock.
Revascularization. Revascularization within one year after
admission was determined using both the hospital discharge
data and physician claims data. For the hospital discharge
data, data were extracted in any of the 10 procedural
diagnosis fields, which were coded by ICD-9-CM. Proce-
dures for the physician claims were coded with the Alberta
Health and Wellness Health Services Codes based on the
Canadian Classification of Procedures (CPX) (22). We
defined three variables for the procedure of care, including
coronary angiography (found in physician claims and coded
as CPX 48.92A, 48.98A, 48.98B, 49.96A, and 49.96B),
percutaneous transluminal coronary angioplasty/stenting
(found in physician claims and coded as CPX 51.59C), and
coronary artery bypass graft surgery (found in physician
claims and coded as CPX 48.0A, 48.12, 48.12A, 48.13,
48.13A, 48.14, 48.14A, 48.15A, 48.15B, 48.15C, 48.15D,
48.15E, 48.15F, 48.15G, 48.15H, and 48.19A).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
CPX  Canadian Classification of Procedures
ICD-9-CM  International Classification of Disease-
Ninth Revision-Clinical Modification
RB  receptor blocker
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Physician and hospital characteristics. The specialty of
the most responsible physician at the index admission was
grouped into two categories: nonspecialist (general or family
practitioners) or other internal medicine specialist/
subspecialist for the index admission. Cardiology specialist/
subspecialist was also identified among internal medicine
specialists/subspecialists. All hospitalizations for heart fail-
ure (newly diagnosed or previously diagnosed) during the
period 1994–1995 to 1999–2000 were used to estimate the
most responsible physicians’ annual volume, crediting any
listing as the most responsible physician or consultation
during hospitalization. The volume was classified into
quartiles.
HOSPITAL FACTORS. We noted the following hospital en-
vironment factors: 1) hospital type (see subsequently); 2)
remote distance to hospital (see subsequently); 3) hospital
beds per capita in each health region (all active hospitals’
acute care beds in each year per health region were recorded
in the provincial data bases); 4) hospital bed turnover ratio
(number of hospital admissions divided by the number of
hospital beds in the specific hospital on the date of the heart
failure admission; 5) occupancy rate (total monthly length of
stay per hospital divided by the total number of beds in each
hospital on the date of the CHF admission); 6) transfer to
hospital by ambulance, as defined in hospital chart abstract;
7) weekend/holiday admission date; 8) admission time
between 6:00 PM to 8:00 AM; 10) emergent admission; and
11) special care (intensive care) unit admission.
HOSPITAL TYPE. The hospital location was classified into
rural, regional, and metropolitan, considering the service
population size for each hospital and whether the hospital
had angiography capability. Rural hospitals admitting heart
failure patients were categorized into two groups based on
the 50th percentile of heart failure hospital discharges
between April 1, 1994, and March 31, 2000. The hospital
types included: 1) rural hospitals with a low volume (n 77;
200 cases); 2) rural hospitals with a high volume (n  25;
204 to 646 cases); 3) regional hospitals (n  5; 238 to 646
cases) located in one of the five nonmetropolitan regional
health care cities; 4) metropolitan hospitals (n  6; 327 to
2,199 cases) located in the metropolitan health region of
Calgary and Edmonton without angiography capability; and
5) metropolitan hospitals (n  3; 1,793 to 2,700 cases)
located in the metropolitan health regions of Calgary and
Edmonton with angiography capability.
REMOTE DISTANCE TO HOSPITAL. The residence of each
hospital and patient was mapped to the center of a postal
code, and “crow flies” distances between centroids were
calculated. The nearest hospital distance (one each for rural,
regional, and metropolitan hospitals) to the patient’s resi-
dence location was obtained for rural residents. Urban
resident to hospital distances were designated as zero.
Distances 50 km were defined as remote.
Prescription characteristics. All seniors registered with
the Alberta Health Care Insurance received subsidized
prescriptions with Alberta Blue Cross. The anonymous
patient identifier for each prescription was merged with the
prescription data base identifying each drug identification
number in order to classify all prescriptions for either
beta-blockers or ACE inhibitors/RBs. Any prescription
within three months before hospital admission or after
hospital discharge was identified. Use of either drug was
assumed if any prescription was linked before or after the
study period after the initial diagnosis of CHF was made.
Relative contraindications to the use of secondary preven-
tion therapy are outlined: 1) for asthma/chronic obstructive
pulmonary disease/other chronic respiratory conditions
(coded as ICD-9 CM 490- 496, 500-505, 506.4), beta-
blockers were contraindicated; 2) for moderate to severe
renal disease (coded as ICD-9-CM 582, 583–583.7, 585,
586, 588), ACE inhibitors/RBs were contraindicated.
Due to the limitations of Blue Cross data and the time lag
between prescription and hospitalization (i.e., 3 months
before admission and after discharge), we only included
patients discharged from October 1, 1994, to March 31,
1995 (last two quarters), for year 1994–1995 and patients
discharged from April 1, 1999, to December 31, 1999 (first
three quarters), for year 1999–2000.
Heart Failure Outcomes
The length of stay was calculated as the days between
discharge and admission dates. Transfers between different
hospitals were attributed to the index admission and cumu-
lative hospital length of stay calculated for an episode of
care. In-hospital mortality was obtained from the hospital
chart abstract. One-year mortality was obtained from vital
statistics declaration of death certificates.
Statistics for outcomes. Adjusted one-year mortality was
calculated using logistic regression. We averaged the pre-
dicted probabilities of mortality for each prescription (E).
The observed mortality (O) divided by the expected rate (E)
generated an O/E ratio for each prescription. The adjusted
mortality was calculated by multiplying each prescription
O/E ratio by the overall mortality. Covariates used for
regression adjustment included patient characteristics (year
of diagnosis, age group, gender, export to another region,
transfer to another acute hospital), severity of illness (ane-
mia, coronary artery disease, hypertension, valvular heart
disease, special care unit admission, overall severity score,
ambulance transfer, cardiac catheterization within one year
from admission), number of comorbidities (i.e., 0, 1, 2, or
2 and transfer from a continuing care institution), and
hospital volumes. All covariates added were significant by
univariate analysis. To verify the logistic regression model
for mortality, we performed a secondary analysis by con-
structing a propensity score using the covariates described
earlier (26). Scores were matched by quintiles and compared
using the Fisher exact test. Modeling used SAS (version
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6.12, 2000, SAS Institute Inc., Cary, North Carolina), and
significance was defined as p  0.05.
RESULTS
During October 1, 1994, to December 31, 1999, there were
11,854 senior hospital admissions for newly diagnosed CHF
(incidence cases), representing 50% of the total senior
hospitalizations (n  23,697) for CHF during this period.
Over the six study years, the use of beta-blockers both
before and after hospitalization increased (Table 1). Over
the six study years, the use of ACE inhibitors or RBs both
before and after hospitalization increased, reaching a peak
during 1997–1998. The one-year mortality rate was similar
over the six study years. A statistical comparison of overall
mortality over time was not attempted, as the first and last
years’ acquisition of cases was not for the entire 12-month
period. Excluding the first and last years of incomplete data,
mortality tended to decrease, consistent with the increased
use of either beta-blockers or ACE inhibitors/RBs.
Compared with those receiving either beta-blockers or
ACE inhibitors/RBs, or both, those not receiving either
prescription were older, fewer resided in a metropolitan
Table 1. Temporal Changes in Seniors (Age 65 Years) Hospitalized With Newly Diagnosed Congestive Heart Failure in Alberta,
Canada During 1994–1995 to 1999–2000
Year
1994–95
Year
1995–96
Year
1996–97
Year
1997–98
Year
1998–99
Year
1999–2000
Average
During
5-Year
Period
Patients with CHF 1,174 2,263 2,372 2,355 2,086 1,604 11,854
Prescription Within 3 Months Before CHF Hospital Admission
Beta-blockers 106 (9.0%) 206 (9.1%) 265 (11.2%) 363 (15.4%) 341 (16.3%) 262 (16.3%) 1,543 (13.0%)
ACE inhibitors/RB agents 148 (12.6%) 414 (18.3%) 535 (22.6%) 808 (34.3%) 674 (32.3%) 491 (30.6%) 3,070 (25.9%)
Prescription Within 3 Months After CHF Hospital Discharge*
Beta-blockers 76 (7.3%) 135 (6.6%) 216 (10.2%) 312 (14.7%) 281 (15.2%) 305 (20.9%) 1,325 (12.5%)
ACE inhibitors/RB agents 324 (31.0%) 485 (23.7%) 1,013 (47.9%) 1,161 (54.9%) 965 (52.0%) 647 (44.3%) 4,595 (43.2%)
Beta-blockers and ACE
inhibitors/RB agents
34 (3.3%) 43 (2.1%) 136 (6.4%) 212 (10.0%) 183 (9.9%) 171 (11.7%) 779 (7.3%)
One-year mortality† 211 (22.8%) 544 (27.4%) 551 (26.8%) 538 (25.6%) 491 (26.5%) 346 (24.1%) 2,681 (25.9%)
*Excludes in-hospital deaths. †Excludes in-hospital deaths and patients not registered at the end of the fiscal year in the health insurance registry. Note: we included only patients
discharged from October 1, 1994, to March 31, 1995 (last two quarters) for year 1994–95 and patients discharged from April 1, 1999, to December 31, 1999 (first three quarters)
for year 1999–2000. Patient prescription categorization was not mutually exclusive. Data are presented as the number (%) of subjects.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; RB  receptor blocker.
Table 2. Severity of Illness and Comorbidity in Seniors (Age 65 Years) Hospitalized With CHF in Alberta, Canada During
1994–1995 to 1999–2000
Patients With Post-Use
of Beta-Blockers Only
(n  546)
Patients With Post-Use
of ACE Inhibitors/RB
Agents Only
(n  3,816)
Patients With Post-Use
of Beta-Blockers and
ACE Inhibitors/RB
Agents (n  779)
Patients Without Post-Use
of Beta-Blockers or ACE
Inhibitors/RB Agents
(n  5,497)
Age (yrs) 77.4  6.7 78.9  7.5 76.8  7.0 80.2  7.9
Female 306 (56.0%) 2,081 (54.5%) 386 (49.6%) 2,873 (52.3%)
Metropolitan resident regions
(Calgary and Edmonton)
258 (47.3%) 1,534 (40.2%) 352 (45.2%) 2,160 (39.3%)
Export 42 (7.7%) 250 (6.6%) 61 (7.8%) 329 (6.0%)
Comorbidity
Mean  SD 0.9  1.0 1.0  0.9 0.9  0.9 1.0  1.0
None 215 (39.4%) 1,371 (35.9%) 293 (37.6%) 1,903 (34.6%)
One 193 (35.3%) 1,476 (38.7%) 310 (39.8%) 2,088 (38.0%)
More than one 138 (25.3%) 969 (25.4%) 176 (22.6%) 1,506 (27.4%)
Severity
Anemia 82 (15.0%) 548 (14.4%) 93 (11.9%) 908 (16.5%)
Electrolyte disturbance 47 (8.6%) 302 (7.9%) 38 (4.9%) 506 (9.2%)
Coronary artery disease 262 (48.0%) 1,432 (37.5%) 408 (52.4%) 1,895 (34.5%)
Hypertension 199 (36.4%) 1,167 (30.6%) 287 (36.8%) 1,334 (24.3%)
Valvular heart disease 90 (16.5%) 665 (17.4%) 148 (19.0%) 770 (14.0%)
Ventricular arrhythmia 15 (2.7%) 131 (3.4%) 23 (3.0%) 121 (2.2%)
Hypotension and shock 11 (2.0%) 59 (1.5%) 9 (1.2%) 86 (1.6%)
Severity score 5.8  2.8 6.1  3.0 5.5  2.6 6.4  2.9
Data are presented as the mean value  SD or number (%) of patients.
Abbreviations as in Table 1.
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region, and more had greater comorbidity and severity of
illness (Table 2). Compared with those receiving either
beta-blockers or ACE inhibitors/RBs, or both, those not
receiving either prescription were more likely to be admitted
into a small rural hospital, less likely to be admitted into a
metropolitan hospital with angiography capability, more
likely to have a general practice physician as the most
responsible physician, less likely to have an internal medi-
cine or cardiology consultation, less likely to have a most
responsible physician with a high volume of similar cases,
and less likely to receive cardiac catheterization or admission
to a special care unit (Table 3). One-year crude mortality
was higher in those not receiving either beta-blockers or
ACE inhibitors/RBs than in those receiving either drug or
both.
Adjusted one-year mortality (Table 4) was lower in
Table 3. Physician and Hospital Factors for Seniors (Age 65 Years) Hospitalized With Newly Diagnosed CHF in Alberta, Canada,
During April 1, 1994, to March 31, 2000
Patients With
Post-Use of
Beta-Blockers
Only (n  546)
Patients With
Post-Use of
ACE Inhibitors/RB
Agents Only
(n  3,816)
Patients With
Post-Use of
Beta-Blockers and
ACE Inhibitors/RB
Agents (n  779)
Patients Without
Post-Use of
Beta-Blockers or
ACE Inhibitors/RB
Agents (n  5,497)
Hospital size
Rural, 200 cases 96 (17.6%) 795 (20.8%) 129 (16.6%) 1,298 (23.6%)
Rural, 200 to 646 cases 111 (20.3%) 817 (21.4%) 170 (21.8%) 1,262 (23.0%)
Regional 62 (11.4%) 564 (14.8%) 94 (12.1%) 688 (12.5%)
Metropolitan without angiography 133 (24.4%) 901 (23.6%) 167 (21.4%) 1,278 (23.2%)
Metropolitan with angiography 144 (26.4%) 739 (19.4%) 219 (28.1%) 971 (17.7%)
General/family practitioner first listed
as most responsible physician
306 (56.0%) 2,596 (68.0%) 415 (53.3%) 4,056 (73.8%)
Any internal medicine
specialist/subspecialist listed as
most responsible physician
317 (58.1%) 1,985 (52.0%) 464 (59.6%) 2,455 (44.7%)
Any cardiologist specialist listed as
most responsible physician
167 (30.6%) 726 (19.0%) 255 (32.7%) 871 (15.8%)
Mean (median) volume (by quartile)
of CHF cases seen by most
responsible physician
57.7 (34%) 51.7 (27) 62.8 (34) 44.5 (25)
Transferred to another acute care
hospital
11 (2.0%) 50 (1.3%) 10 (1.3%) 50 (0.9%)
Special care unit admission 141 (25.8%) 631 (16.5%) 217 (27.9%) 733 (13.3%)
Admitted from emergency room 279 (51.1%) 1,713 (44.9%) 469 (60.2%) 1,775 (32.3%)
One-year mortality* 85 (15.6%) 805 (21.1%) 108 (13.9%) 1,683 (32.3%)
Cardiac catheterization 82 (15.0%) 260 (6.8%) 136 (17.5%) 244 (4.4%)
Percutaneous transluminal coronary
angioplasty/stent
16 (2.9%) 31 (.8%) 27 (3.5%) 26 (0.5%)
Coronary artery bypass graft surgery 18 (3.3%) 50 (1.3%) 20 (2.6%) 49 (.9%)
*Excludes in-hospital deaths. Data are presented as the number (%) of patients, unless otherwise indicated.
Abbreviations as in Table 1.
Table 4. Adjusted Mortality in Seniors (Age 65 Years) Hospitalized With Newly Diagnosed
CHF in Alberta, Canada During 1995–1996 to 1999–2000
Prescription Within 3 Months After Discharge*
One-Year Mortality
(95% CI)
No prescription of beta-blocker or ACE inhibitors/RB agents (n  5,497) 29.9% (28.8–31.0)
Beta-blocker alone (n  546) 18.2% (14.2–22.2)
Beta-blocker with contraindication (n  86) 18.9% (10.1–27.6)
Beta-blocker without contraindication (n  460) 18.0% (13.6–22.5)
ACE inhibitors/RB agents (n  3,816) 22.3% (20.9, 23.7)
ACE inhibitors/RB agents with contraindication (n  141) 22.1% (16.6–27.6)
ACE inhibitors/RB agents without contraindication (n  3,675) 22.3% (20.9–23.8)
Combination beta-blocker and ACE inhibitors/RB agents (n  779) 16.6% (13.3–20.0)
Combination beta-blocker and ACE-inhibitors/RB agents with any
contraindication (n  156)
17.6% (11.2–24.1)
Combination beta-blocker and ACE inhibitors/RB agents without any
contraindication (n  623)
16.3% (12.3–20.3)
*Excludes in-hospital deaths. Beta-blockers where contraindicated for asthma/chronic obstructive pulmonary disease/other
chronic respiratory conditions, and ACE inhibitors or RB agent were contraindicated for moderate to severe renal disease, as
defined by hospital abstracted diagnosis (see Methods).
CI  confidence interval; other abbreviations as in Table 1.
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seniors with prescriptions for beta-blockers or ACE inhib-
itors/RBs, or both. The comparison of patients with and
without relative contraindications for either beta-blockers or
ACE inhibitors/RBs did not alter the benefit toward de-
creased mortality. Propensity analysis results were analogous
to those for logistic regression. For each quintile of propen-
sity score, patients who did not take either beta-blockers or
ACE inhibitors/RBs had higher one-year mortality than
those who took at least one. For each quintile of propensity
score, patients who used only beta-blockers did not have a
statistically different one-year mortality than those who used
ACE inhibitors/RBs only. In one quintile group, the
one-year mortality was higher for patients who used beta-
blockers only, compared with patients who used both
beta-blockers and ACE inhibitors/RBs. For the other four
quintile groups, the mortality was not statistically different.
For one quintile group, the one-year mortality was higher
for patients who used ACE inhibitors/RBs only, compared
with patients who used both beta-blockers and ACE inhib-
itors/RBs. For the other four quintile groups, the mortality
was not statistically different.
DISCUSSION
We believe that this is the first population-based study to
demonstrate an association between the use beta-blockers,
ACE inhibitors/RBs, or combination of both, and de-
creased mortality after CHF hospitalization. The absolute
adjusted risk reduction comparing no prescription with both
beta-blockers and ACE inhibitors/RBs was 13.3% (i.e.,
29.9% to 16.6%), for a relative adjusted risk reduction of
44%. The absolute risk reduction in this population cohort
was greater than that noted in clinical trials (9,27–29), likely
as a result of the higher mortality in our study, which
enrolled unselected patients (30,31). Our population cohort
was not stratified by left ventricular systolic or diastolic
function, and the majority was in an age group (75 years
old) that has been traditionally excluded in clinical trials.
The benefits of ACE inhibitors have been noted in another
study, irrespective of left ventricular ejection fraction (32).
The critical message of this study for the clinician is that the
mortality reduction with the use of beta-blockers and ACE
inhibitors/RBs found in clinical trials may be generalizable
to all patients hospitalized with CHF. If true, future clinical
trials of beta-blockers and ACE inhibitors/RBs in CHF
(33) should not be restricted to only those with a docu-
mented low ejection fraction, as these patients constitute
only a proportion of the at-risk population (34,35).
Both ACE inhibitors and RBs are underutilized in
patients with CHF (36,37). Familiarity with medications
may increase utilization, which would be an explanation for
the greater use in specialists/subspecialists and high-
practice-volume physicians noted in this study and others
(38). Passive and active dissemination of practice guidelines
are not always successful strategies in increasing utilization
(33,36). Some programs have been more successful at
including a local provincial program, which was associated
with the peak use of ACE inhibitors/RBs in 1997–1998
(39). There exists a paradox of need where those most likely
to benefit from practice guidelines (low volume practice,
smaller rural hospitals) are least likely to receive them (40).
Relative contraindications to ACE inhibitors/RBs, such
as renal failure, or beta-blockers, such as asthma and chronic
obstructive pulmonary disease, may decrease utilization,
even though a benefit persists (41,42). We found that the
association with decreased mortality persisted even in those
patients with relative contraindications, unlike in a previous
study (43). The poorer prognosis for CHF in population-
based cohorts (44–47), as well as the fact that many deaths
are not related to CHF in the general population composed
of older patients, may make physicians even more reluctant
to adopt clinical recommendations concerning the use of
these therapeutic agents (9,48,49). Our data do not support
the exclusion of all patients with contraindications, as
defined by hospital abstracts.
Study limitations. This study has several limitations.
Population-based administrative data base research is highly
generalizable, although limited in clinical details. We at-
tempted to adjust for case severity and comorbidity, al-
though these data may not have captured all important
variations. The diagnosis of CHF from hospital discharge
data may underestimate the true prevalence of this disease
(50,51). We constructed an episode of care by attributing
re-admissions within the first day of discharge back to the
original index admission. Our length of stay was attributed
to the presenting hospital rather than all hospitals in which
care could have been rendered. We potentially missed
incident cases if a contact with the health system was never
made. We also may have similarly misclassified some
prevalent cases as incident cases; however, this was likely
infrequent, as hospitalized patients were excluded if a
previous ambulatory diagnosis of CHF had been made.
Another potential bias in this study is that patients who died
soon after hospital discharge were given a prescription but
never had the opportunity to fill this prescription. These
patients would have been misclassified into the no prescrip-
tion group. We do not believe that this effect was large, as
only 4.9% of deaths were within the first week of hospital
discharge. The large relative risk reduction was influenced
by the asymmetry in the severity of illness and comorbidity
in those not receiving prescriptions, as well as their higher
mortality rate. We attempted to account for these differ-
ences by adjustment and propensity score; however, residual
confounding because of unmeasured or unaccounted differ-
ences between those patients who did and did not receive
prescription may still have existed.
Conclusions. We believe that this is the first population-
based study to demonstrate an association between de-
creased mortality and beta-blockers, ACE inhibitors/RBs,
or a combination of both, after CHF hospitalization. This
study did not exclude those without documented left ven-
tricular systolic or diastolic function or those in the age
1443JACC Vol. 42, No. 8, 2003 Johnson et al.
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group 75 years. As such, the effectiveness of beta-blockers
and ACE inhibitors/RBs should be tested in clinical trials
enrolling the entire population of hospitalized patients with
CHF.
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